| KODIAK SCIENCES DL-,0001 |
| USA |
| Gesundheit |
| US50015M1099 / A2N6P0 |
| K27 (Frankfurt) / KOD (NASDAQ) |
| FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD |
| - |
| https://kodiak.com/ |
|
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-pr..
>Volltext.. |
| 1992.72 Mio. EUR |
| 1980.96 Mio. EUR |
| - |
| -179.91 Mio. EUR |
| -198.41 Mio. EUR |
| -3.59 EUR |
| 134.18 Mio. EUR |
| 145.82 Mio. EUR |
| - |
| 3.42 |
| - |
| -13.3% |
| - |
| - |
| - |
| - |
| KODIAK SCIENCES |
| 18.05.26 |
|